A New Publication Highlights the Use of cResponse in the Assessment of Response to Treatments for Pancreatic Cancer
Curesponse discusses with the Jerusalem Post its innovative cResponse™ test that helps tailor the optimal treatment for breast cancer patients.
Curesponse discuss with the Jerusalem Post its cResponse test that can predict which drugs will benefit individual cancer patients.
Curesponse Presents Positive Preliminary Clinical Results from a Multi-Center UK Study at AACR
Curesponse discusses its cancer prediction cResponse™ test with Ynet (in hebrew)
Curesponse Announces Clalit Health Services, Largest Israeli HMO, to Provide Commercial Coverage for the cResponse™ test
Curesponse shows applicability with next generation immuno-oncology drugs
Curesponse to exhibit at ASCO, 2022
Curesponse to present at BIOMED Israel, 2022
Curesponse publishes new clinical study in Nature Cancer
Want to know more?